ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban (EMIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02975453
Recruitment Status : Active, not recruiting
First Posted : November 29, 2016
Last Update Posted : November 26, 2018
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer

Brief Summary:
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain

Condition or disease Intervention/treatment
Atrial Fibrillation Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study Type : Observational
Actual Enrollment : 1463 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study of Risk Factors of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With a Direct Oral Anticoagulant (Rivaroxaban)
Actual Study Start Date : December 5, 2016
Estimated Primary Completion Date : December 15, 2019
Estimated Study Completion Date : February 28, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban

Group/Cohort Intervention/treatment
Rivaroxaban
Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
Drug: Rivaroxaban (Xarelto, BAY59-7939)
As prescribed by the treating physician




Primary Outcome Measures :
  1. 2MACE score [ Time Frame: At baseline ]
    MACE: Major adverse cardiovascular events. 2MACE: History of Myocardial infarction/ Cardiac revascularization and Metabolic Syndrome, Age >75 years, Congestive heart failure (ejection fraction <40%), Thrombo-Embolism

  2. Occurrence of MACE to evaluate the performance of the 2MACE index [ Time Frame: At 2 years and 6 months or early termination ]
    Percentage of patients with MACE including fatal/nonfatal myocardial infarction, cardiac revascularization and cardiovascular death


Secondary Outcome Measures :
  1. Incorporation of additional risk factors to the 2MACE index or replacing some of the existing ones [ Time Frame: At baseline ]
    Risk factors to the 2MACE index (e.g. body mass index, smoking, drugs use, estimated glomerular filtration rate, structural cardio-pathology)

  2. Occurrence of major cardiovascular events (fatal/nonfatal myocardial infarction, cardiac revascularization and cardiovascular death) [ Time Frame: At baseline, at 1 year, at 2 years, at 2 years and 6 months or early termination ]
  3. Occurrence of stroke [ Time Frame: At baseline, at 1 year, at 2 years, at 2 years and 6 months or early termination ]
  4. Occurrence of transient ischemic attack (TIA) [ Time Frame: At baseline, at 1 year, at 2 years, at 2 years and 6 months or early termination ]
  5. Occurrence of systemic embolism [ Time Frame: At baseline, at 1 year, at 2 years, at 2 years and 6 months or early termination ]
  6. Thromboembolic risk based on the CHADS2 score [ Time Frame: At baseline ]
    CHADS2: Cardiac Failure, Hypertension, Age, Diabetes, Stroke

  7. Thromboembolic risk based on the CHA2DS2-VASC [ Time Frame: At baseline ]
    CHA2DS2-VASc:Cardiac failure, Hypertension, Age ≥75, Diabetes, Stroke -Vascular disease, Age and Sex category

  8. Number of MACEs occurring during the study [ Time Frame: At 1 year, at 2 years, at 2 years and 6 months or early termination ]
  9. Patients' profile [ Time Frame: At baseline ]
    Baseline patients' profile defined by: sociodemographic data, anthropometric data, previous relevant medical history, cardiac medical history distinct to atrial fibrillation, comorbidities (renal failure, left ventricular dysfunction, hypertension, thyroid dysfunction, liver failure, alcoholism)

  10. Number of cases (frequency) of metabolism syndrome at enrollment with/without the occurrence of myocardial infarction or coronary revascularization [ Time Frame: At baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients diagnosed with non-valvular atrial fibrillation who are under rivaroxaban treatment and that attend the Cardiology Units at Spanish hospitals and private clinics
Criteria

Inclusion Criteria:

  • Adult patients aged 18 years or older.
  • Patients with diagnosis of NVAF.
  • Patients treated with rivaroxaban from at least six months prior to the study inclusion.
  • Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent.

Exclusion Criteria:

  • Patients participating in an investigational program with interventions outside of routine clinical practice.
  • Patients who initiate treatment with rivaroxaban after the start of the study inclusion period.
  • Prosthetic heart valves or the presence of any severe valvulopathies.
  • Patients with severe cognitive impairment.
  • Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases.
  • Patients with active cancer.
  • Patients with liver insufficiency (eg. cirrhosis).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02975453


Locations
Spain
Multiple Locations, Spain
Sponsors and Collaborators
Bayer
Janssen Research & Development, LLC
Investigators
Study Director: Bayer Study Director Bayer

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02975453     History of Changes
Other Study ID Numbers: 18884
First Posted: November 29, 2016    Key Record Dates
Last Update Posted: November 26, 2018
Last Verified: November 2018

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants